Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Edgewise Therapeutics stock
Learn how to easily invest in Edgewise Therapeutics stock.
Edgewise Therapeutics Inc is a biotechnology business based in the US. Edgewise Therapeutics shares (EWTX) are listed on the NASDAQ and all prices are listed in US Dollars. Edgewise Therapeutics employs 42 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Edgewise Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – EWTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Edgewise Therapeutics stock price (NASDAQ: EWTX)Use our graph to track the performance of EWTX stocks over time.
Edgewise Therapeutics shares at a glance
|Latest market close||$9.60|
|52-week range||$5.41 - $22.98|
|50-day moving average||$10.25|
|200-day moving average||$10.75|
|Wall St. target price||$24.25|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$2.89|
Buy Edgewise Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Edgewise Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Edgewise Therapeutics price performance over time
|1 week (2022-09-22)||4.35%|
|1 month (2022-08-30)||-3.81%|
|3 months (2022-06-30)||20.60%|
|6 months (2022-03-30)||3.67%|
|1 year (2021-09-30)||-42.17%|
|2 years (2020-09-26)||N/A|
|3 years (2019-09-26)||N/A|
|5 years (2017-09-26)||N/A|
Is Edgewise Therapeutics stock undervalued or overvalued?
Valuing Edgewise Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edgewise Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edgewise Therapeutics's P/E ratio
Edgewise Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Edgewise Therapeutics shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Edgewise Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Edgewise Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-12.75%|
|Return on equity TTM||-20.76%|
|Market capitalisation||$576.8 million|
TTM: trailing 12 months
Edgewise Therapeutics share dividends
We're not expecting Edgewise Therapeutics to pay a dividend over the next 12 months.
Edgewise Therapeutics overview
Edgewise Therapeutics, Inc. , a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. .
Edgewise Therapeutics in the news
Purple Innovation and Edgewise Therapeutics Stock See Action From Activist Investors
Frequently asked questionsWhat percentage of Edgewise Therapeutics is owned by insiders or institutions?
Currently 0.907% of Edgewise Therapeutics shares are held by insiders and 88.583% by institutions. How many people work for Edgewise Therapeutics?
Latest data suggests 42 work at Edgewise Therapeutics. When does the fiscal year end for Edgewise Therapeutics?
Edgewise Therapeutics's fiscal year ends in December. Where is Edgewise Therapeutics based?
Edgewise Therapeutics's address is: 3415 Colorado Avenue, Boulder, CO, United States, 80303 What is Edgewise Therapeutics's ISIN number?
Edgewise Therapeutics's international securities identification number is: US28036F1057
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert